Cargando…
The role of glatiramer acetate in the early treatment of multiple sclerosis
The treatment of the underlying disease process causing multiple sclerosis has continued to evolve since the initial approval of interferon-beta-1b in 1993. Current emphasis is on early treatment, including treatment after a single clinical attack (clinically isolated syndrome). The assessment of wh...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2898171/ https://www.ncbi.nlm.nih.gov/pubmed/20628633 |
_version_ | 1782183483532115968 |
---|---|
author | Brandes, David W |
author_facet | Brandes, David W |
author_sort | Brandes, David W |
collection | PubMed |
description | The treatment of the underlying disease process causing multiple sclerosis has continued to evolve since the initial approval of interferon-beta-1b in 1993. Current emphasis is on early treatment, including treatment after a single clinical attack (clinically isolated syndrome). The assessment of which disease modifying medication to use as initial therapy has continued to remain a combination of science and the art of medicine. Equally important are the assessment of treatment failure and the subsequent choice of medication change. This article will present scientific information, as well as information about clinical decision making, about these choices, with emphasis on the changing role of glatiramer acetate in this process. |
format | Text |
id | pubmed-2898171 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-28981712010-07-13 The role of glatiramer acetate in the early treatment of multiple sclerosis Brandes, David W Neuropsychiatr Dis Treat Expert Opinion The treatment of the underlying disease process causing multiple sclerosis has continued to evolve since the initial approval of interferon-beta-1b in 1993. Current emphasis is on early treatment, including treatment after a single clinical attack (clinically isolated syndrome). The assessment of which disease modifying medication to use as initial therapy has continued to remain a combination of science and the art of medicine. Equally important are the assessment of treatment failure and the subsequent choice of medication change. This article will present scientific information, as well as information about clinical decision making, about these choices, with emphasis on the changing role of glatiramer acetate in this process. Dove Medical Press 2010 2010-06-24 /pmc/articles/PMC2898171/ /pubmed/20628633 Text en © 2010 Brandes publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Expert Opinion Brandes, David W The role of glatiramer acetate in the early treatment of multiple sclerosis |
title | The role of glatiramer acetate in the early treatment of multiple sclerosis |
title_full | The role of glatiramer acetate in the early treatment of multiple sclerosis |
title_fullStr | The role of glatiramer acetate in the early treatment of multiple sclerosis |
title_full_unstemmed | The role of glatiramer acetate in the early treatment of multiple sclerosis |
title_short | The role of glatiramer acetate in the early treatment of multiple sclerosis |
title_sort | role of glatiramer acetate in the early treatment of multiple sclerosis |
topic | Expert Opinion |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2898171/ https://www.ncbi.nlm.nih.gov/pubmed/20628633 |
work_keys_str_mv | AT brandesdavidw theroleofglatirameracetateintheearlytreatmentofmultiplesclerosis AT brandesdavidw roleofglatirameracetateintheearlytreatmentofmultiplesclerosis |